MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

Introducing P&T TV

We would like to encourage you to send us your own short videos about your P&T committee experiences. Tell us what topics are hot at your committee meetings and your video might get posted to this site. All entries will be considered for posting. Contact Editor Sonja Sherritze, at 267-685-2779 or by email at ssherritze@medimedia.com.

We would also like your feedback. So take a tour around the site and let us know what you think. Thanks for reading P&T, and for visiting PTCommunity. Remember, P&T is the place to be!


Overview of the LUME-lung 1, Phase 3 Trial

Martin Reck, MD, PhD, says that combination treatment with nintendanib was significantly superior to docetaxel monotherapy in non-small-cell lung cancer after one chemotherapy regimen (LUME-lung 1, Phase 3).

2013 American Society of Clinical Oncology

Rapid Onset of Effect with Apremilast for Behçet’s Syndrome: A Phase 2 Study

Gülen Hatemi, MD, of Istanbul University, Cerrahpasa Medical School in Istanbul, Turkey, says that the beneficial effects of apremilast in this multicenter, randomized, placebo-controlled study started within 2 weeks and were sustained during treatment — but they soon disappeared after apremilast was stopped at week 24.

American College of Rheumatology

Dapagliflozin for Hypertension in Diabetes

Michael Weber, MD, of the State University of New York (SUNY) Downstate College of Medicine in Brooklyn, NY, says that dapagliflozin 10 mg, an investigational sodium-glocuse co-transporter 2 inhibitor, effectively reduced both glycosylated hemoglobin and systolic blood pressure in two studies.

American Heart Association Scientific Sessions 2013

Apremilast Offers a Strong Oral Choice for Psoriatic Arthritis Patients

Kenneth Gordon, Professor of Dermatology at Northwestern University, talks about the oral medication apremilast, recently approved for psoriatic arthritis. Apremilast offers a major benefit to patients — especially those who don’t want an injectable medication. Its response rates are high and it is very well tolerated.

American Academy of Dermatology 2014

Psoriasis Patients' Options Include Effective Oral and Injectible Drugs

There are two basic delivery choices for psoriasis medications, says Kenneth Gordon, Professor of Dermatology at Northwestern University. While biologic therapies given as shots have higher response rates, new oral medications such as apremilast and tofacitinib work well, cost less, and may appeal to patients who don’t like injectibles.

American Academy of Dermatology 2014

2 Lenalidomide Regimens in The FIRST Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma Patients: Initial Phase 3 Results

Thierry Facon, MD, of Hopital Claude Huriez, CHRU Lille in France, concludes that in newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation, the FIRST trial establishes continuous lenalidomide therapy as a new standard of care.

American Society of Hematology 2013

Looking for Predictive Factors in Advanced Breast Cancer: BOLERO-2, Phase 3

Hope Rugo, MD, discusses the direction of current research into biologic agents for the treatment of advanced breast cancer at the American Society of Clinical Oncology meeting June 3, 2013, in Chicago.

2013 American Society of Clinical Oncology

Cangrelor Versus Clopidogrel in Intraprocedural Stent Thrombosis (IPST): CHAMPION PHOENIX

Philippe Genereux, MD, of the Angiographic Core Laboratory, Cardiovascular Research Foundation in New York, NY, says that cangrelor was associated with significant reductions in the key endpoints of stent thrombosis and IPST when compared with clopidogrel.

Transcatheter Cardiovascular Therapeutics

Bivalirudin Versus Heparins With or Without Glycoprotein Inhibitors: EUROMAX

Phillippe Gabriel Steg, MD, of the Hopital Bichat in Paris, France, discusses The European Ambulance ACS AngioX trial (EUROMAX), the first study to evaluate anticoagulant therapy options prior to hospital admission and in conjunction with the newer P2Y12 inhibitors. The findings support a role for bivalirudin in the pre-hospital setting.

Transcatheter Cardiovascular Therapeutics

Bivalirudin, Cangrelor, and Stent Thombosis: New Trials Raise More Questions

C. Michael Gibson, MS, MD, of Harvard Medical School, discusses important aspects of the HORIZONS-AMI and EUROMAX trials and tackles the question of whether a longer infusion of bivalirudin could lead to a reduced risk of stent thrombosis within 24 hours.

Transcatheter Cardiovascular Therapeutics

Cangrelor Decreases Ischemia-Driven Revascularization: A Meta-Analysis

Harvey White, MD, of Auckland, New Zealand, says that cangrelor significantly reduced the rate of ischemic events, including stent thrombosis during percutaneous coronary intervention (PCI) with no significant increase in severe bleeding.

American Heart Association Scientific Sessions 2013

Phase 2 Study of Intralesional PV-10 (Rose Bengal) in Metastatic Melanoma

Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology at St. Luke’s University Health Network in Bethlehem, PA, and Professor of Medicine at Temple University in Philadelphia, PA, discusses several scenarios in which PV-10 might be used if it is ultimately approved for patients with advanced melanoma.

2013 European Cancer Congress

Inhibiting the mTOR Pathway in Trastuzumab-Resistant, HER-2-Positive Advanced Breast Cancer Patients: BOLERO-3, Phase 3

Ruth O’Regan, MD, says that the combination of everolimus plus vinorelbine and trastuzumab may be considered an appropriate option in trastuzumab-resistant, HER-2-positive advanced breast cancer (BOLERO-3, Phase 3).

2013 American Society of Clinical Oncology

Apremilast in DMARD-Naïve Patients With Psoriatis Arthritis: PALACE 4 (Phase 3)

Alvin Wells, MD, PhD, of the Rheumatology and Immunotherapy Center in Oak Creek, Wisconsin, says that apremilast, which modulates intracellular inflammatory mediators, produced clinicallly significant improvements in signs and symptoms in treated patients in this 52-week study.

American College of Rheumatology

A Phase II Trial Finds Ixekizumab “Extremely Effective” and Safe for Psoriasis

Kenneth Gordon, Professor of Dermatology at Northwestern University, discusses phase II safety and efficacy studies of the anti–interleukin-17 monoclonal antibody ixekizumab for psoriasis. In a year-long extension of a 12-week trial, ixekizumab was “extremely effective” at sustaining responses, leading to complete clearance in 40% to 50% of patients. The drug was also very well tolerated, with no safety signals that raised concern.

American Academy of Dermatology 2014